114-LB: GX-G6, a Novel Long-Acting Glucagon-Like Peptide Receptor Agonist: Result of Phase I Study in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-114-lb
Abstract: GLP-1 receptor agonists are widely used in T2DM. GX-G6 is a hyFcTM fused long acting GLP-1, and is a proposed alternative to other GLP-1 agents. In this phase I, randomized, double-blind, placebo-controlled, single ascending dose… read more here.
Keywords: 114 novel; novel long; study; receptor ... See more keywords
948-P: A Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136, a Novel Long-Acting Glucagon Analogue, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-948-p
Abstract: HM15136 is a novel long-acting glucagon analogue with an extended half-life. In vivo efficacy studies of HM15136 in animal models showed its therapeutic potential in congenital hyperinsulinism, hypoglycaemia post-bariatric surgery, and obesity. We performed a… read more here.
Keywords: glucagon; hm15136 novel; long acting; novel long ... See more keywords